Absci Corporation, a clinical-stage biopharmaceutical company, has announced the commencement of its first clinical trial for ABS-101, an AI-designed biologic aimed at treating inflammatory bowel disease $(IBD)$. The Phase 1 trial is currently underway with the first healthy volunteers dosed in a randomized, placebo-controlled study. ABS-101, engineered using Absci's generative AI platform, boasts superior potency and reduced immunogenicity, offering potential improvements in efficacy and patient convenience with quarterly dosing. Interim data from this trial is anticipated in the second half of 2025. Additionally, Absci is advancing ABS-201, an AI-designed anti-prolactin receptor antibody for treating androgenetic alopecia, with preclinical data showing promising results. The Phase 1 trials for ABS-201 are expected to commence in early 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.